Literature DB >> 21895408

Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice.

L Dai1, L Cheng, X Zhang, Q Jiang, S Zhang, S Wang, Y Li, X Chen, T DU, Y Yang, H Tian, P Fan, N Yan, L Dai1, Y Wei, H Deng.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) plays an important role in the tumor formation and metastasis. In this study, short hairpin RNA targeting STAT3 was cloned into pGenesil-2 plasmid vector and the effects of STAT3 silencing in 4T1 breast cancer cells were analyzed both in vitro and in vivo. Forty-eight hours after transfecting with pSi-STAT3, the expression level of STAT3, the upstream regulator and downstream targets were measured using Western blot. Moreover, the effects of pSi-STAT3 on migration and invasion in 4T1 cells were tested using wound-healing and tube formation assay. Furthermore, 4T1 subcutaneous mice model was used to evaluate the effects of pSi-STAT3 on tumor growth and metastasis. Proliferation, apoptosis, angiogenesis in tumor tissues and lung metastases were measured by PCNA, TUNEL, and CD31 immunostaining, respectively. Our results indicated that siRNA targeting STAT3 could significantly silence STAT3 expression in 4T1 breast cancer cells and result in inhibition of 4T1 breast cells migration and HUVECs tube formation. In vivo, pSi-STAT3 delayed tumor growth (pknockdown of STAT3 by plasmid-based siRNA might be a potential therapy against breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21895408     DOI: 10.4149/neo_2011_06_538

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Vishakha V Ambardekar; Stephen M Curran; Shetty Ravi Dyavar; Lora L Arnold; Samuel M Cohen; Devendra Kumar; Yazen Alnouti; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Nanomedicine       Date:  2021-02-03       Impact factor: 5.307

2.  Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.

Authors:  X Zhang; M A Blaskovich; K D Forinash; S M Sebti
Journal:  Br J Cancer       Date:  2014-07-01       Impact factor: 7.640

3.  SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin.

Authors:  Lei Dai; Xueliang Cui; Xin Zhang; Lin Cheng; Yi Liu; Yang Yang; Ping Fan; Qingnan Wang; Yi Lin; Junfeng Zhang; Chunlei Li; Ying Mao; Qin Wang; Xiaolan Su; Shuang Zhang; Yong Peng; Hanshuo Yang; Xun Hu; Jinliang Yang; Meijuan Huang; Rong Xiang; Dechao Yu; Zongguang Zhou; Yuquan Wei; Hongxin Deng
Journal:  Nat Commun       Date:  2016-06-29       Impact factor: 14.919

4.  RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy.

Authors:  Jing Gan; Fangfang Wang; Dezhi Mu; Yi Qu; Rong Luo; Qiu Wang
Journal:  Oncol Lett       Date:  2016-10-14       Impact factor: 2.967

5.  Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Stephen M Curran; Shetty Ravi Dyavar; Devendra Kumar; Yazen Alnouti; Don W Coulter; Anthony T Podany; Rakesh K Singh; Joseph A Vetro
Journal:  Noncoding RNA       Date:  2022-01-13

6.  TIPE1 function as a prognosis predictor and negative regulator of lung cancer.

Authors:  Xiaocheng Wu; Yunmiao Ma; Ji Cheng; Xia Li; Hui Zheng; Li Jiang; Renjie Zhou
Journal:  Oncotarget       Date:  2017-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.